Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 14/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.60 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.50 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.50 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6986148 | 0.85 | PTGS2 (0.64) | PTGS2PTGS1MAPK13MAPK12MAPK11 | |
| SCHEMBL6782968 | 0.81 | PTGS2 (0.68) | PTGS2PTGS1 | |
| SCHEMBL19953044 | 0.81 | PTGS2 (0.68) | PTGS2PTGS1 | |
| SCHEMBL6362727 | 0.76 | MAPK13 (0.53) | PTGS2PTGS1MAPK13MAPK12MAPK11 | |
| SCHEMBL6179878 | 0.75 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL6181102 | 0.75 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL6180868 | 0.70 | PTGS2 (0.55) | PTGS2PTGS1MAPK13MAPK12MAPK11 | |
| SCHEMBL15208252 | 0.70 | PTGS2 (0.72) | PTGS2PTGS1 | |
| SCHEMBL161234 | 0.70 | CES2 (0.40) | PTGS1 | |
| SCHEMBL28797653 | 0.69 | PTGS2 (0.54) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030114456-A1 | Novel heterocylic compounds with anti-inflamatory activity | J. URIACH & CIA, S.A. (ES) | 2003-06-19 | — | — | US | disclosed |
| EP-1281709-A1 | NOVEL HETEROCYCLIC COMPOUNDS WITH ANTI-INFLAMMATORY ACTIVITY | J. URIACH & CIA. S.A. (ES) | 2003-02-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114456-A1 | Novel heterocylic compounds with anti-inflamatory activity | IL1B, IL1A, NFKBIA | PTGS2 23/4885PTGS1 7/4885MAPK13 1800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.